RESUMEN
Mesalazine (5-aminosalicylic acid, 5-ASA),is an anti-inflammatory drug well-established as first-line treatment in the management of inflammatory bowel disease. Nephritic colic has been described as an uncommonside effect, but very few mesalazine nephrolithiasis have been published in the literature, probably due to its underdiagnosis for not using appropriate methodology for calculi analysis. We present two cases of lithiasis in patients treated with mesalazine at high dosage, an adverse effect to betaken into account as a drug lithiasis and which is not even mentioned in the patient information leaflet.
La mesalazina (ácido 5-aminosalicilico,5-ASA) es un fármaco antiinflamatorio utilizado en primera línea del tratamiento de la enfermedad inflamatoria intestinal. Aunque se ha descrito la presentación de cólicos nefríticos como efecto adverso con su uso, apenas se encuentran publicados casos de nefrolitiasis medicamentosa por mesalazina, probablemente infradiagnósticado por no utilizar la metodología adecuada para el análisis de los cálculos. Presentamos dos casos de litiasis en dos pacientes tratados a altas dosis de mesalazina, efecto adversoa tener en cuenta y que ni siquiera es citado en la ficha técnica del medicamento.
Asunto(s)
Cálculos , Cálculos Renales , Litiasis , Nefrolitiasis/inducido químicamente , Antiinflamatorios no Esteroideos/efectos adversos , Humanos , Riñón , MesalaminaRESUMEN
Plasma treatments had emerged as a useful technique to improve seed germination. In this work we investigate the influence of different irrigation conditions and plasma treatments on the germination of nasturtium seeds. During plasma treatment, seeds experience a progressive weight loss as a function of treatment time that has been associated to water release, a process that is more pronounced after longer plasma treatment times. Seeds treated for short times (<30 s) are able to germinate more efficiently than untreated specimen under hydric stress (drought conditions), while plasma treatments for longer times (up to 300 s) impaired germination independently on irrigation conditions. Characterization analysis of plasma treated seeds by FTIR-ATR, SEM/EDX and XPS showed that plasma treatment affected the chemical state of pericarp while, simultaneously, induced a considerable increase in the seeds water uptake capacity. The decrease in germination efficiency found after plasma treatment for long times, or for short times under optimum irrigation conditions, has been attributed to that the excess of water accumulated in the pericarp hampers the diffusion up to the embryo of other agents like oxygen which are deemed essential for germination.
Asunto(s)
Riego Agrícola , Germinación , Nasturtium/crecimiento & desarrollo , Gases em Plasma/farmacología , Semillas/crecimiento & desarrollo , Temperatura , Nasturtium/efectos de los fármacos , Semillas/efectos de los fármacos , AguaRESUMEN
La mesalazina (ácido 5-aminosalicilico,5-ASA) es un fármaco antiinflamatorio utilizado en primera línea del tratamiento de la enfermedad inflamatoria intestinal. Aunque se ha descrito la presentación de cólicos nefríticos como efecto adverso con su uso, apenas se encuentran publicados casos de nefrolitiasis medicamentosa por mesalazina, probablemente infradiagnósticado por no utilizar la metodología adecuada para el análisis de los cálculos. Presentamos dos casos de litiasis en dos pacientes tratados a altas dosis de mesalazina, efecto adverso a tener en cuenta y que ni siquiera es citado en la ficha técnica del medicamento
Mesalazine (5-aminosalicylic acid, 5-ASA), is an anti-inflammatory drug well-established as first-line treatment in the management of inflammatory bowel disease. Nephritic colic has been described as an uncommon side effect, but very few mesalazine nephrolithiasis have been published in the literature, probably due to its underdiagnosis for not using appropriate methodology for calculi analysis. We present two cases of lithiasis in patients treated with mesalazine at high dosage, an adverse effect to be taken into account as a drug lithiasis and which is not even mentioned in the patient information leaflet